AbbVie licenses Nxera’s EP4 agonist IBD program for up to $1.5 billion
AbbVie signed an exclusive global licensing agreement with Nxera Pharma for the EP4 receptor agonist NXE0033744, a novel oral drug for inflammatory bowel disease. The deal provides AbbVie with worldwide rights to develop and commercialise the candidate and includes a $100 million upfront cash payment to Nxera, with up to $1.37 billion in development and commercial milestones. Nxera expects to recognise the upfront as JPY 15.78 billion of revenue in its FY2026 fourth quarter and has raised its FY2026 sales forecast to JPY 48.8 billion, with core operating income of JPY 22.8 billion.
Why it matters
The upfront cash and higher FY2026 sales forecast improve Nxera’s near‑term financial position, while the milestone potential adds upside if the drug progresses. AbbVie adds a differentiated IBD candidate to its immunology pipeline, potentially expanding its product base beyond existing biologics.
Key facts
- 1AbbVie will pay $100 million upfront for exclusive worldwide rights to NXE0033744. tradingview.com
- 2The agreement includes up to $1.37 billion in development and commercial milestone payments. pharmaceutical-technology.com
- 3Nxera expects to recognise JPY 15.78 billion from the upfront payment as revenue in FY2026 Q4, assuming an exchange rate of JPY 157.8 per US $. rttnews.com
- 4Nxera revised its FY2026 net‑sales forecast to JPY 48.8 billion. rttnews.com
- 5Nxera revised its FY2026 core operating income forecast to JPY 22.8 billion. rttnews.com
- 6NXE0033744 has completed a Phase 1 trial showing gut‑selective activity. pharmaceutical-technology.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.